Clinical Trial Detail

NCT ID NCT02768792
Title High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications

acute myeloid leukemia

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.